Bangalore: Biocon has announced that Biocon Pharma Limited, a wholly owned subsidiary of the Company, in partnership with Carnegie Pharmaceuticals LLC, has received tentative approval from the U.S. Food and Drug Administration (U.S. FDA) for the Abbreviated New Drug Application (ANDA) for Rifaximin Tablets, 550 mg.

Rifaximin tablets are a rifamycin antibacterial indicated for reducing the risk of overt hepatic encephalopathy (HE) recurrence and to treat irritable bowel syndrome with diarrhea (IBS-D) in adults.

Irritable Bowel Syndrome is a common gastrointestinal disorder that affects the large intestine, leading to symptoms like abdominal pain, bloating, and changes in bowel habits.

Read also: Biocon Biologics, Amgen strike settlement, clear path for Bosaya, Aukelso in

See Full Page